Screening Strategy for Gastric Cancer Prevention

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorNational Taiwan University Hospital

About this trial

There are still some unsolved questions regarding population-based screening program for H. pylori infection to prevent gastric cancer, such as how to perform the optimal screening strategies. A prospective, randomized trial will be conducted to compare the acceptability, compliance (/adherence), and accuracy of diagnostic tests in a population-based H. pylori screening and gastric cancer prevention program.

Initially, we planned to recruit 10,000 adults aged ≥20 years who had not previously undergone H. pylori screening or treatment. Eligible participants were to be randomly allocated in a 1:1:1:1 ratio to one of four groups, each receiving a different combination of diagnostic tests. However, a preliminary analysis led to a recalculation of the required sample size. Following the approval of an Institutional Review Board (IRB) amendment, enrollment was discontinued for Group B (HpSA method) and Group D (Two-stage screening method). The final number of participants enrolled in Group B and Group D was 852 and 851, respectively. Groups A (UBT method) and Group C (standard method) will continue to enroll participants through an additional 1:1 randomization until each group reaches a total of 1,350 participants.

Eligibility criteria

Qualifiers

Adults aged 20 years or older

Never screened and treated for H. pylori infection

Disqualifiers

Ever undergone gastrectomy

Patients with gastric cancer

Have been screened or tested for H. pylori infection

Ever received H. pylori eradication therapy

Trial design

Treatments tested in this trial

  • UBT
  • HPSA
  • UBT and HPSA
  • Serology (two stage)

Treatment groups

4,403 Participants
are divided into 4 treatment groups